Tag Archives: FFIV

U.S. Hot Stocks Quick Recap: F5 Networks, Flamel, Healthways, KAR Auction, Maxygen, Amgen, Teva

Morgan Stanley (NYSE:MS) shatter stock rating on IT-equipment manufacturer F5 Networks, Inc (NASDAQ:FFIV) to equalweight, mentioning field work “paints a picture of a maturing firm with world-class, fully featured, however in many cases over-featured products.”

F5 Networks, Inc. (NASDAQ:FFIV) last …

Posted in Latest Headlines, Services | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off

F5 Networks (NASDAQ:FFIV) Misses Quarterly Outlook; Tumbles to Record Low – FFIV, RDWR, CSCO, PKT

Shares of the Seattle, Washington based F5 Networks, Inc (NASDAQ:FFIV) plunged in over 2 years low level after the company’s preliminary quarterly profit and revenue failed to meet its estimate as North American sales tumbled.

The maker of data-management equipment …

Posted in Latest Headlines, Technology | Tagged , , , , , , , , , , , | Comments Off

Radware (NASDAQ:RDWR) Cuts Outlook for Fiscal First Quarter

Radware Ltd (NASDAQ:RDWR) reported on Friday preliminary results for the Q1 of 2013.
Radware is an application delivery and application security solutions provider for virtual and cloud data centers.
Quarterly non-GAAP EPS are now projected to be $0.30 a share, …

Posted in Main Post, Technology | Tagged , , , , , , , , , , , | Comments Off

Tech Sector News Buzz: Exide Technologies (NASDAQ:XIDE), F5 Networks (NASDAQ:FFIV) – XIDE, FFIV, JNPR, RDWR, RMBS

Technology sector finished lower on last trading session and sector plunged -0.97%. If we look at the key percentage decliners so Radware Ltd (NASDAQ:RDWR) and F5 Networks, Inc (NASDAQ:FFIV) were prominent stocks while key percentage gainer was Rambus Inc (NASDAQ:RMBS).…

Posted in Latest Headlines, Technology | Tagged , , , , , , , , , , , , , , | Comments Off

Key Percentage Decliners Recap: Rigel Pharmaceuticals (NASDAQ:RIGL), F5 Networks (NASDAQ:FFIV)

Rigel Pharmaceuticals, Inc (NASDAQ:RIGL) is down over 35% to $4.83. AstraZeneca plc (ADR) (NYSE:AZN) reported that a phase III study to assess the efficacy and safety of drug applicant Fostamatinib for rheumatoid arthritis met one primary goal, while it missed …

Posted in Latest Headlines | Tagged , , , , , | Comments Off

F5 Networks (NASDAQ:FFIV) Shatters Second Quarter Outlook

F5 Networks, Inc (NASDAQ:FFIV) shattered its fiscal Q2 financial outlook on Thursday, mainly hurt by North America slowdown.

The Seattle, Washington based F5 Networks presently forecasts fiscal Q2 earnings in the range of $0.79 per share to $0.80 per share, …

Posted in Main Post, Technology | Tagged , , , , , , , , , , , | Comments Off